.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) Rameen Kasana
Tue, Jun 17, 2025, 12:32 PM 2 min read
In This Article:
UroGen Pharma Ltd. (NASDAQ:URGN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at H.C. Wainwright significantly raised the rating for UroGen Pharma Ltd. (NASDAQ:URGN) to Buy from Neutral, with a price target of $50.00. This revision was after Thursday’s regulatory approval of Zusduri, priced at $21,500 per dose.
With the stock price increasing by over 100% in the past five days and the potential to rise even further, investors have little to worry about. UroGen Pharma Ltd. (NASDAQ:URGN), exhibiting an impressive gross margin of around 90%, is set for a product launch aimed at non-muscle invasive bladder cancer, which affects as many as 59,000 patients annually in the U.S. alone. By 2026, the treatment is anticipated to achieve expected performance, generating $1 billion in sales.
A scientist examining a sample of hydrogel in a laboratory setting.
While clarity around the approval path for UGN-103 is sought by the analysts, the management believes potential changes to the clinical trial strategy insignificantly impact its financial outlook. Having said that, UGN-103 is crucial for advancing the giant’s franchise exclusivity beyond early 2031.
UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company founded in 2004. This New Jersey-based company develops and markets treatments for urothelial and specialty cancers. The company’s core offerings include RTGel and Jelmyto, with UGN-102, UGN-103, and UGN-104 being the lead product candidates.
While we acknowledge the potential of URGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Comments